Immune system may target other remote areas of the brain to improve stroke recovery

Immune system may target other remote areas of the brain to improve stroke recovery

New University of Kentucky research shows that the immune system may target other remote areas of the brain to improve recovery after a stroke. The study in mice, published in PNAS by researchers from UK's College of Medicine, University of Texas Southwestern Medical Center and University of Pennsylvania reveals that after a stroke, B cells migrate to remote regions of the brain that are known to generate new neuronal cells as well as regulate cognitive and motor functions. B cells are a type of white blood cell that makes antibodies. Less known and studied, however, is that B cells can produce neurotrophins that regulate the development and growth of neurons in the brain. An ischemic stroke is the most common type of stroke that happens when an artery in the brain becomes clogged, typically by a blood clot. After ischemic stroke, it is well-known that B cells travel to the site of the stroke as part of the immune response. But this new study shows that B cells may also move into multiple areas of the brain – both injured and uninjured. This is rather unique because it broadens our idea that we need to look at other areas of the brain when studying stroke. These areas are really critical for functional recovery so they could potentially be targets for drug development or therapies." Ann Stowe, UK associate professor in the Department of Neurology and senior author of the study Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More